On Apr. 19, 2021, CureVac and Celonic Group announced their partnership for the production of CureVacﾒs mRNA-based COVID-19 vaccine candidate, CVnCoV.

The parties entered into a commercial supply agreement to produce CureVacﾒs coronavirus vaccine candidate at Celonicﾒs state-of-the-art commercial manufacturing facility for biologics and ATMPs, in Heidelberg, Germany. In total Celonic was prepared to manufacture more than 100 million doses of CVnCoV. More than 50 million doses are expected to be produced before the end of 2021.